In silico analysis of multiple targets (HER2 receptor and DNA) inhibition by natural isoquinoline derivatives for breast cancer treatment
by Lokesh Kumar Agarwal
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 15, No. 3, 2022

Abstract: Breast cancer is one of the major challenges for women's health worldwide. Approximately 15-30% of breast cancer aggressiveness is caused by over-reactivity of the HER2 receptor enzyme. Hence, the inhibition of HER2 has become a promising approach for the treatment of human breast cancer. In this in silico study, the binding interactions of five natural isoquinoline derivatives with the HER2 enzyme (PDB Id 3PPO) and double-stranded DNA (PDB Id 1Z3F) were investigated. The average binding free energy of ligands with HER2 and DNA receptors ranges from -8.52 kcal/mol to -6.59 kcal/mol and from -9.76 kcal/mol to -6.47 kcal/mol respectively. The drug-likeness competency of ligand molecules was also investigated using the Lipinski rule of five (Ro5). Lamellarin A5 was found to show better inhibition strength for both targets as compared to reference compounds (Neratinib & Afatinib) with improved drug-likeness properties. The outcomes of the study suggest Lamellarin A5 for further in vitro/in vivo analysis.

Online publication date: Thu, 12-Jan-2023

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com